Panelists explore the latest insights on CTDNA in muscle-invasive bladder cancer and its impact on immunotherapy decision-making and patient outcomes.
Alan Tan, MD
Advertisement
Articles by Alan Tan, MD
Panelists discuss new findings on adjuvant immunotherapy for high-risk bladder cancer revealing significant insights into patient outcomes and treatment strategies.
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.
Advertisement
Latest Updated Articles
Episode 14: Multidisciplinary Care Insights Across World GU 2025Published: September 18th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
FDA Approves Ziftomenib in R/R NPM1-Mutated Acute Myeloid Leukemia
3
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
4
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
5
